Thyroid [I]MIBG Uptake in Parkinson's Disease and Diabetes Mellitus

Overview

Journal IBRO Neurosci Rep

Specialty Neurology

Date 2023 Apr 3

PMID 37006721

Authors

Tatyana D Fedorova

Karoline Knudsen

Thorsten K Rasmussen

Jacob Horsager

Adjmal Nahimi

Casper Skjaerbaek

Eva Schaeffer

Daniela Berg

Astrid J Terkelsen

Per Borghammer

Affiliations

Soon will be listed here.

Abstract

Thyroid [I]MIBG uptake is proposed as a tool for differentiating between Parkinson's disease (PD) and diabetes mellitus (DM) on [I]MIBG scintigraphies since both patient groups show decreased cardiac uptake. One study compared thyroid [I]MIBG uptake in DM and PD patients and reported reduced [I]MIBG uptake only in the PD group. Here, we investigated thyroid [I]MIBG uptake in patients with PD and DM and found severely reduced thyroid [I]MIBG uptake in DM. Larger studies are needed to substantiate whether DM patients are more or less likely to exhibit decreased thyroid MIBG uptake compared to controls and PD patients.

Citing Articles

Iodine-123 Metaiodobenzylguanidine (I-123 MIBG) in Clinical Applications: A Comprehensive Review.

Chang M, Peng C, Chen C, Shih Y, Chen J, Tai Y Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770405 PMC: 11676292. DOI: 10.3390/ph17121563.

References

Horsager J, Andersen K, Knudsen K, Skjaerbaek C, Fedorova T, Okkels N . Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. Brain. 2020; 143(10):3077-3088. DOI: 10.1093/brain/awaa238. View

Taki J, Nakajima K, Hwang E, Matsunari I, Komai K, Yoshita M . Peripheral sympathetic dysfunction in patients with Parkinson's disease without autonomic failure is heart selective and disease specific. taki@med.kanazawa-u.ac.jp. Eur J Nucl Med. 2000; 27(5):566-73. DOI: 10.1007/s002590050544. View

Giubbini R, Milan E, Marcassa C, Paghera B, Fracassi F, Camoni L . 1-23I-MIBG thyroid uptake: Implications for MIBG imaging of the heart. J Nucl Cardiol. 2015; 23(6):1335-1339. DOI: 10.1007/s12350-015-0142-3. View

Varley B, Gow M, Cho Y, Benitez-Aguirre P, Cusumano J, Pryke A . Higher frequency of cardiovascular autonomic neuropathy in youth with type 2 compared to type 1 diabetes: Role of cardiometabolic risk factors. Pediatr Diabetes. 2022; 23(7):1073-1079. PMC: 9805172. DOI: 10.1111/pedi.13393. View

Treglia G, Stefanelli A, Cason E, Cocciolillo F, Di Giuda D, Giordano A . Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple-system atrophy: a systematic review and a meta-analysis. Clin Neurol Neurosurg. 2011; 113(10):823-9. DOI: 10.1016/j.clineuro.2011.09.004. View

Solanki K, Bomanji J, Moyes J, Mather S, Trainer P, Britton K . A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992; 13(7):513-21. DOI: 10.1097/00006231-199207000-00006. View

Jaiswal M, Divers J, Urbina E, Dabelea D, Bell R, Pettitt D . Cardiovascular autonomic neuropathy in adolescents and young adults with type 1 and type 2 diabetes: The SEARCH for Diabetes in Youth Cohort Study. Pediatr Diabetes. 2018; 19(4):680-689. PMC: 5938122. DOI: 10.1111/pedi.12633. View

Postuma R, Berg D, Stern M, Poewe W, Olanow C, Oertel W . MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015; 30(12):1591-601. DOI: 10.1002/mds.26424. View

Goldstein D, Holmes C, Dendi R, Bruce S, Li S . Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology. 2002; 58(8):1247-55. DOI: 10.1212/wnl.58.8.1247. View

10.

Pontico M, Brunotti G, Conte M, Corica F, Cosma L, de Angelis C . The prognostic value of I-mIBG SPECT cardiac imaging in heart failure patients: a systematic review. J Nucl Cardiol. 2021; 29(4):1799-1809. PMC: 9345809. DOI: 10.1007/s12350-020-02501-w. View

11.

Hartikainen J, Mustonen J, Kuikka J, Vanninen E, Kettunen R . Cardiac sympathetic denervation in patients with coronary artery disease without previous myocardial infarction. Am J Cardiol. 1997; 80(3):273-7. DOI: 10.1016/s0002-9149(97)00345-7. View

12.

Scholte A, Schuijf J, Delgado V, Kok J, Bus M, Maan A . Cardiac autonomic neuropathy in patients with diabetes and no symptoms of coronary artery disease: comparison of 123I-metaiodobenzylguanidine myocardial scintigraphy and heart rate variability. Eur J Nucl Med Mol Imaging. 2010; 37(9):1698-705. PMC: 2918794. DOI: 10.1007/s00259-010-1442-0. View

13.

Miyamoto K, Saiki S, Matsumoto H, Suzuki A, Yamashita Y, Iseki T . Systemic Metabolic Alteration Dependent on the Thyroid-Liver Axis in Early PD. Ann Neurol. 2022; 93(2):303-316. PMC: 10092289. DOI: 10.1002/ana.26510. View

14.

Jang W, Kim J, Cho J, Ahn J, Choi Y, Kim H . Thyroid MIBG uptake in Parkinson's disease with diabetes mellitus. Clin Auton Res. 2013; 23(4):221-4. DOI: 10.1007/s10286-013-0204-z. View

15.

Watanabe K, Takahashi T, Miyajima S, Hirokawa Y, Tanabe N, Kato K . Myocardial sympathetic denervation, fatty acid metabolism, and left ventricular wall motion in vasospastic angina. J Nucl Med. 2002; 43(11):1476-81. View

16.

Orimo S, Suzuki M, Inaba A, Mizusawa H . 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012; 18(5):494-500. DOI: 10.1016/j.parkreldis.2012.01.009. View

17.

Matsui H, Udaka F, Oda M, Tamura A, Kubori T, Nishinaka K . Metaiodobenzylguanidine (MIBG) uptake in Parkinson's disease also decreases at thyroid. Ann Nucl Med. 2005; 19(3):225-9. DOI: 10.1007/BF02984609. View

18.

Braak H, Sastre M, Bohl J, de Vos R, Del Tredici K . Parkinson's disease: lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta Neuropathol. 2007; 113(4):421-9. DOI: 10.1007/s00401-007-0193-x. View

19.

Tipre D, Goldstein D . Cardiac and extracardiac sympathetic denervation in Parkinson's disease with orthostatic hypotension and in pure autonomic failure. J Nucl Med. 2005; 46(11):1775-81. View